BRC Therapeutics strengthens its clinical leadership team with the appointment of Kimberly Spancake, a veteran drug development executive with over two decades of experience at major pharmaceutical firms.
The announcement is a senior director-level clinical appointment (Kimberly Spancake, Senior Director, Clinical) dated Nov. 5, 2026, with no financial terms, timelines, trial data or guidance. A non-executive hire of this kind does not change the company's cash position, pipeline readouts or valuation, so no material price reaction is expected.
No financial figures, trial dates or guidance are given; the release only describes the new senior director's 25-plus years of drug development experience at GW Pharmaceuticals and Jazz Pharmaceuticals.
BRC Therapeutics has named industry veteran Kimberly Spancake as its new Senior Director of Clinical. Spancake joins the clinical-stage firm with over 25 years of experience in drug development, having previously held roles at GW Pharmaceuticals and Jazz Pharmaceuticals.
No financial figures, trial dates or guidance are given; the release only describes the new senior director's 25-plus years of drug development experience at GW Pharmaceuticals and Jazz Pharmaceuticals.